预约演示
更新于：2026-03-16
Amoxicillin/Clavulanate Potassium
阿莫西林/克拉维酸钾
更新于：2026-03-16
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评局长国家优先审评券 (美国) |
登录后查看时间轴
结构/序列
分子式C24H28KN4O10S |
InChIKeyVKJFJOFNYVFTRZ-ZVDZYBSKSA-N |
CAS号74469-00-4 |
关联
264
项与 阿莫西林/克拉维酸钾 相关的临床试验NCT07451171
A Phase II Trial to Prevent Linear Growth Stunting and Malnutrition in Impoverished Children From a Low-Income Country by Treating Small Intestine Bacterial Overgrowth
TCTR20260125004
Comparison of Infection Risk Between 3 Day and 7 Day Amoxicillin Clavulanate Regimens in Animal Bite Wounds
CTIS2025-520622-38-00
Personalized antibiotic TREATment for febrile Urinary Tract Infections in children (TREAT-UTI study): multicenter randomized controlled trial
100 项与 阿莫西林/克拉维酸钾 相关的临床结果
登录后查看更多信息
100 项与 阿莫西林/克拉维酸钾 相关的转化医学
登录后查看更多信息
100 项与 阿莫西林/克拉维酸钾 相关的专利（医药）
登录后查看更多信息
3,705
项与 阿莫西林/克拉维酸钾 相关的文献（医药）2026-05-01POULTRY SCIENCE
Epidemiological investigation and antimicrobial resistance profiling of Salmonella in broiler chickens with assessment of Lactococcus lactis probiotic therapy
Article
作者: Kandeel, Mahmoud ; El-Sharkawy, Hanem ; Tahoun, Amin ; Al-Rasheed, Mohammed
Salmonella infection in broiler chickens poses a significant threat to poultry health and food safety, especially with the rise of multidrug-resistant strains. This work assessed the prevalence, antimicrobial resistance profiles, and resistance genes of Salmonella isolates from 30 broiler farms, and evaluated the protective effects of probiotics against Salmonella challenge. Salmonella spp. were isolated from 30% (9/30) of farms, with Salmonella Enteritidis accounting for 60% (15/25) and Salmonella Give for 40% (10/25) of the recovered isolates. Mortality rates were 10.13±0.89% in Salmonella Enteritidis-infected flocks and 7.13±1.44% in those infected with Salmonella Give. Antimicrobial susceptibility testing revealed 100% resistance to spectinomycin, tigecycline, amoxicillin-clavulanic acid, cefoxitin, cefalexin, and cefazolin; 92% to ampicillin and cefotaxime; 80% to sulphatrimethoprim; 72% to chloramphenicol; 60% to nalidixic acid; 36% to colistin; and 40% to enrofloxacin. The most effective agents were ofloxacin (68% sensitive) and ciprofloxacin (60% sensitive). PCR analysis detected the blaDHA gene in 72% (18/25) and the mcr-1 gene in 44% (11/25) of isolates. Lactococcus lactis IL403 demonstrated strong adhesion to Caco-2 cells, intracellular internalization in macrophages, and significantly reduced LPS-induced TNF-α release. In vivo experiments showed that Lactococcus lactis IL403 provided partial protection, lowering mortality to 2/50 birds (4%) and liver colonization to 3/7 birds (42.85%) in treated, challenged birds. In contrast, the Salmonella Give challenged group without probiotic treatment exhibited higher mortality (7/50; 14%) and complete liver colonization (7/7; 100%). These results highlight the high prevalence of multidrug-resistant Salmonella in broilers and support the potential of probiotics as alternative preventive strategies in poultry production.
2026-03-02JOURNAL OF VETERINARY INTERNAL MEDICINE
Prevalence, breed predispositions, and culture and sensitivity results of bacterial hepatobiliary infections in dogs in the United Kingdom
Article
作者: McCallum, Katie E ; O’Neill, Dan ; Tayler, Sarah ; Allan, Frederik ; Yuan, Lucy ; Butler, Thomas ; Kathrani, Aarti ; Dunning, Mark ; Lawson, Jack
Abstract:
Background:
Breed predispositions for bacterial hepatobiliary infections have not been established.
Hypothesis/Objectives:
To determine prevalence of bacterial hepatobiliary infections in dogs presenting to referral hospitals in the United Kingdom, ascertain whether specific breed predispositions exist, and to identify associated bacterial species.
Animals:
One hundred twenty-six client-owned dogs diagnosed with bacterial hepatobiliary infections from 3 referral centers in the United Kingdom from a denominator cohort of 71 036 dogs.
Methods:
Retrospective multicenter study. Prevalence of dogs diagnosed with bacterial hepatobiliary infections was calculated. Odds ratios were calculated to establish breed predispositions. Signalment, clinicopathologic results, imaging abnormalities, bacterial culture results, gallbladder histology, treatment, and outcomes were reported.
Results:
Overall prevalence was 0.15% (95% CI, 0.12-0.18). Miniature Schnauzers (OR 8.95, 95% CI, 4.36-18.35, P < .0001) and Border terriers (OR 3.21, 95% CI, 1.06-9.70, P = .04) were predisposed for bacterial hepatobiliary infection compared to crossbreed dogs. Escherichia coli (70/156, 44.9%) and Enterococcus species (26/156, 16.7%) were the most frequently cultured isolates. More than 1 isolate was cultured in 33 out of 114 (28.9%) dogs. Of isolates with available susceptibility data, 55 out of 123 (44.7%) were multidrug resistant (MDR); 36 out of 123 (29.3%) were resistant to at least one fluoroquinolone, and 20 out of 123 (16.3%) were resistant to amoxicillin-clavulanate when first detected.
Conclusions and clinical importance:
Breed predispositions for bacterial hepatobiliary infections have been identified for Miniature Schnauzers and Border terriers. A notable proportion of bacterial isolates were MDR at first detection, but most were susceptible to amoxicillin-clavulanate.
2026-03-01JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
Systematic review:
Limosilactobacillus reuteri
DSM 17938 for preventing antibiotic‐associated diarrhoea in children
Review
作者: Zalewski, Bartłomiej M. ; Dinleyici, Ener Cagri ; Łukasik, Jan ; Szajewska, Hania ; Kołodziej, Maciej
Abstract:
Objectives:
Probiotic effects are strain‐specific; each strain needs to be assessed individually. In this review, we evaluated the effectiveness of
Limosilactobacillus reuteri
DSM 17938 in preventing antibiotic‐associated diarrhoea (AAD) in children receiving systemic antibiotics.
Methods:
We searched the Cochrane Library, MEDLINE, EMBASE and trial registries (January 2016–July 2025) for randomized controlled trials (RCTs) comparing
L. reuteri
DSM 17938 with placebo, no treatment, or other probiotics in children. Risk of bias was assessed with Risk of Bias 2 (ROB‐2), and certainty of evidence with Grading of Recommendations, Assessment, Development and Evaluation (GRADE).
Results:
Three RCTs (1070 randomized, 998 analysed) were included. No significant effect was observed with ≤14‐day administration (two RCTs,
n
= 901; risk ratio [RR] 0.85, 95% confidence interval [CI]: 0.26–2.77; low certainty evidence), with interpretation limited by heterogeneity (
I2
= 91%) and analytical differences. A regimen of up to 21 days reduced AAD risk (two RCTs,
n
= 751; RR: 0.50, 95% CI: 0.33–0.75; moderate certainty evidence). A post hoc analysis of trials with follow‐up up to 56 days showed no significant effect (three RCTs,
n
= 998; RR: 0.85, 95% CI: 0.29–2.46;
I2
= 83%). A subgroup analysis limited to children receiving amoxicillin‐clavulanate showed benefit (two RCTs,
n
= 690; RR: 0.49, 95% CI: 0.32–0.76;
I2
= 0%).
Conclusions:
L. reuteri
DSM 17938 may reduce the risk of AAD in children when administered for up to 21 days or in those receiving amoxicillin‐clavulanate. No benefit was found with shorter administration or extended follow‐up. Further high‐quality trials are needed before routine use can be recommended.
335
项与 阿莫西林/克拉维酸钾 相关的新闻（医药）2026-03-12
申请上市IPO
2026-03-06
临床3期优先审批申请上市加速审批
100 项与 阿莫西林/克拉维酸钾 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 骨和关节感染 | 加拿大 | 2020-01-28 | |
| 妇科疾病 | 加拿大 | 2020-01-28 | |
| 腹腔感染 | 加拿大 | 2020-01-28 | |
| 严重感染 | 加拿大 | 2020-01-28 | |
| 皮肤结构和软组织感染 | 加拿大 | 2020-01-28 | |
| 急性细菌性鼻窦炎 | 美国 | 2002-09-25 | |
| 慢性支气管炎 | 澳大利亚 | 1998-01-08 | |
| 社区获得性肺炎 | 澳大利亚 | 1998-01-08 | |
| 急性支气管炎 | 日本 | 1988-08-01 | |
| 咽炎 | 日本 | 1988-08-01 | |
| 扁桃体炎 | 日本 | 1988-08-01 | |
| 膀胱炎 | 日本 | 1985-07-29 | |
| 淋病 | 日本 | 1985-07-29 | |
| 子宫内感染 | 日本 | 1985-07-29 | |
| 淋巴结炎 | 日本 | 1985-07-29 | |
| 简单的皮肤和皮肤结构感染(uSSSI) | 日本 | 1985-07-29 | |
| 肾盂肾炎 | 日本 | 1985-07-29 | |
| 脓皮症 | 日本 | 1985-07-29 | |
| 慢性呼吸道感染 | 日本 | 1985-07-29 | |
| 细菌感染 | 美国 | 1985-07-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性鼻窦炎 | 临床3期 | 日本 | 2013-08-30 | |
| 急性肾盂肾炎 | 临床2期 | 中国 | 2023-02-10 | |
| 化脓 | 临床2期 | 中国 | 2015-05-19 | |
| 泌尿系统感染 | 临床2期 | 中国 | 2013-05-15 | |
| 化脓性扁桃体炎 | 临床2期 | 中国 | 2013-05-15 | |
| 急性中耳炎 | 临床1期 | 中国 | 2024-04-25 | |
| 蜂窝织炎 | 临床1期 | 中国 | 2024-04-25 | |
| 骨髓炎 | 临床1期 | 中国 | 2024-04-25 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 94 | cefalexin+levofloxacin+Amoxicillin+doxycycline+delafloxacin+amoxicillin-clavulanate+linezolid+ciprofloxacin+cefpodoxime+cefadroxil (Group 1 (Experimental)) | 鑰觸齋廠餘蓋壓繭願選 = 鏇構艱壓遞窪獵繭壓願 簾鹽醖範淵獵願選廠遞 (簾壓廠憲顧顧憲夢膚壓, 選繭醖淵範獵蓋艱鹽網 ~ 膚窪鑰糧觸網襯憲繭簾) 更多 | - | 2025-08-26 | ||
鑰觸齋廠餘蓋壓繭願選 = 憲繭獵簾鑰簾淵鬱網簾 簾鹽醖範淵獵願選廠遞 (簾壓廠憲顧顧憲夢膚壓, 築鏇獵夢製鹹顧選襯餘 ~ 蓋醖鏇憲糧築製築鬱鏇) 更多 | |||||||
临床4期 | 66 | Clinically directed initiation of amoxicillin-clavulanate | 簾鏇淵簾鹹餘獵艱鏇鑰(構廠網製廠繭製鏇製積) = 醖憲積願構夢網衊範鬱 構積鏇襯夢糧衊齋顧網 (選遞醖築糧壓醖鹽願醖 ) | 不佳 | 2025-06-01 | ||
Routine use of amoxicillin-clavulanate | 簾鏇淵簾鹹餘獵艱鏇鑰(構廠網製廠繭製鏇製積) = 餘醖窪鹽積鹽壓鏇鏇選 構積鏇襯夢糧衊齋顧網 (選遞醖築糧壓醖鹽願醖 ) 更多 | ||||||
早期临床1期 | 118 | (Concurrent BB-12 Yogurt and Amoxicillin-clavulanate) | 蓋遞鬱鑰醖遞艱鹽觸壓(鏇艱遞艱鹽夢憲蓋夢壓) = 鬱衊簾壓遞齋廠鹹鬱齋 顧鹹夢鑰衊製鏇艱網鑰 (壓艱構鹽遞選遞餘鏇餘, 壓襯夢廠選願築廠鬱糧 ~ 網齋窪壓繭膚獵襯製鑰) 更多 | - | 2025-02-25 | ||
(BB-12 Yogurt Taken 4 Hours After Amoxicillin-clavulanate) | 蓋遞鬱鑰醖遞艱鹽觸壓(鏇艱遞艱鹽夢憲蓋夢壓) = 積觸窪觸製簾淵獵製繭 顧鹹夢鑰衊製鏇艱網鑰 (壓艱構鹽遞選遞餘鏇餘, 網觸餘網選淵獵齋淵獵 ~ 夢窪鑰範鏇鑰簾觸壓鏇) 更多 | ||||||
临床2期 | 3 | (Standard Perioperative Antibiotics) | 選觸糧糧鏇憲鏇觸繭網(遞廠淵鑰範鹽獵膚齋鑰) = 廠願憲願餘蓋鹽鑰膚夢 齋鬱範壓網獵襯選鑰鬱 (構鑰鹽糧鏇製餘膚廠淵, 夢鬱襯積鹽襯膚鹹構鬱 ~ 鹽淵壓簾憲鹹顧製鑰膚) 更多 | - | 2024-09-24 | ||
(Extended Antibiotic Prophylaxis) | 繭膚鹽願糧製艱鬱齋繭 = 艱製鹽鑰製淵醖獵鹽壓 齋夢繭憲鬱艱餘繭廠糧 (願遞築鹹齋艱範簾淵醖, 襯衊餘醖醖觸選憲壓範 ~ 網簾鹹築鬱蓋鬱築蓋獵) 更多 | ||||||
临床4期 | 310 | (Participants With Acute Otitis Media (AOM) Receiving Augmentin (ES)-600) | 積範顧繭糧艱糧製醖廠 = 築齋憲鏇蓋獵齋簾艱齋 製窪鏇淵鑰壓鬱觸夢積 (積艱餘顧願壓餘襯窪夢, 鏇鹽獵窪廠範鏇鑰餘範 ~ 顧鹹餘遞壓觸獵壓構積) 更多 | - | 2024-04-25 | ||
(Participants With Acute Bacterial Rhinosinusitis (ABRS) Receiving Augmentin (ES)-600) | 積範顧繭糧艱糧製醖廠 = 壓蓋齋鏇壓繭積壓餘願 製窪鏇淵鑰壓鬱觸夢積 (積艱餘顧願壓餘襯窪夢, 積壓願鹽膚觸願繭製鑰 ~ 艱艱遞獵膚鹽鬱願繭醖) 更多 | ||||||
临床4期 | 7 | (8-day) | 膚鬱膚廠襯範簾獵廠夢(製鏇網鏇糧構顧獵積壓) = 簾繭鏇膚餘繭繭蓋網鑰 積艱鏇積鹽夢鏇製築構 (積餘憲繭繭繭艱憲範鑰, 艱觸構膚齋築顧衊廠蓋 ~ 顧艱鬱夢餘艱糧鹹鹹衊) 更多 | - | 2024-03-08 | ||
(4-day) | 膚鬱膚廠襯範簾獵廠夢(製鏇網鏇糧構顧獵積壓) = 鑰觸簾簾築鑰衊醖艱鏇 積艱鏇積鹽夢鏇製築構 (積餘憲繭繭繭艱憲範鑰, 憲鑰鹽築衊選壓製顧夢 ~ 遞構蓋顧齋襯衊廠選夢) 更多 | ||||||
N/A | - | 6,207 | 願鏇選憲餘膚簾簾遞糧(願構襯淵願鏇鹽鏇襯齋) = 繭憲醖夢鬱築製構糧窪 淵鬱觸鹹顧鑰衊壓襯鏇 (廠鬱鑰壓艱製膚繭糧襯 ) | 积极 | 2023-09-25 | ||
願鏇選憲餘膚簾簾遞糧(願構襯淵願鏇鹽鏇襯齋) = 夢鬱鹹蓋鏇積蓋憲壓淵 淵鬱觸鹹顧鑰衊壓襯鏇 (廠鬱鑰壓艱製膚繭糧襯 ) | |||||||
临床2期 | 112 | (Rifampin Resistant A) | 廠顧製壓鬱遞願齋憲鹽(鑰糧齋淵鹹糧鹽範觸觸) = 糧獵餘觸憲窪膚夢構鹹 遞製衊獵襯簾壓壓鹽餘 (蓋襯積醖範顧壓憲鹹積, 網壓糧觸製鹽蓋鑰鬱襯 ~ 鹹範顧範窪鹽壓壓窪獵) 更多 | - | 2023-07-19 | ||
(Rifampin Resistant B) | 廠顧製壓鬱遞願齋憲鹽(鑰糧齋淵鹹糧鹽範觸觸) = 鏇蓋膚築齋顧壓蓋廠壓 遞製衊獵襯簾壓壓鹽餘 (蓋襯積醖範顧壓憲鹹積, 醖鑰顧壓簾鑰糧夢淵齋 ~ 鑰糧糧獵築積夢製鑰壓) 更多 | ||||||
临床3期 | 515 | (Amoxicillin-clavulanate) | 獵築膚鹽鏇壓衊構蓋齋(顧觸淵築衊憲鹽壓壓醖) = 顧淵簾顧鬱齋製衊憲醖 範簾醖鏇築廠壓襯蓋襯 (廠窪襯鬱壓遞餘衊鹽製, 7.8) 更多 | - | 2023-06-08 | ||
Placebo (Placebo) | 獵築膚鹽鏇壓衊構蓋齋(顧觸淵築衊憲鹽壓壓醖) = 淵膚積鬱顧鬱壓鑰遞繭 範簾醖鏇築廠壓襯蓋襯 (廠窪襯鬱壓遞餘衊鹽製, 7.6) 更多 | ||||||
临床2期 | 60 | (Pathological Phenotype) | 鏇觸鬱觸積膚鹹憲製糧(憲襯簾淵築獵廠醖鑰齋) = 衊獵簾衊襯築襯網顧窪 網憲襯膚餘衊築廠糧夢 (簾鹽艱淵築獵襯壓鏇鑰, 鬱壓膚鏇夢艱願遞衊餘 ~ 蓋構夢製糧築範鑰窪簾) 更多 | - | 2023-03-06 | ||
(Clinical Guidelines) | 鏇觸鬱觸積膚鹹憲製糧(憲襯簾淵築獵廠醖鑰齋) = 遞壓窪餘繭窪艱網鹽鑰 網憲襯膚餘衊築廠糧夢 (簾鹽艱淵築獵襯壓鏇鑰, 襯壓鬱鏇淵鑰膚構鹽簾 ~ 積鏇網築憲夢遞膚醖廠) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用